XML 82 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Arrangements (Tables)
 12 Months Ended
Dec. 31, 2013
Collaborative Arrangements  
Schedule of total net revenue recognized

 

 

 
   Year Ended December 31,  
(In thousands)
  2013   2012   2011  

GSK

   $ 4,532   $ 5,613   $ 9,658  

Astellas

     —     125,788     14,854  

Other

     226     4,357     —  
               
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Total net revenue

   $ 4,758   $ 135,758   $ 24,512  
               
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
               
Schedule of revenue recognized from GSK under the LABA collaboration and strategic alliance agreements

 

 

 
   Year Ended December 31,  
(In thousands)
  2013   2012   2011  

Royalty revenue

   $ 1,945   $ —   $ —  

Amortization of intangible assets

     (743 )   —     —  
               
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Net royalty revenue

     1,202     —     —  

LABA collaboration(1)

     1,815     3,629     4,718  

Strategic alliance agreement

     —     —     1,858  

Strategic alliance—MABA program license(2)

     1,515     1,984     3,082  
               
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Total net revenue from GSK

   $ 4,532   $ 5,613   $ 9,658  
               
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
               
(1)
We revised the estimated performance period for the LABA program based on its progress in the fourth quarter of 2011, resulting in an increase to net loss of $0.4 million for the year ended December 31, 2011. Deferred revenue under this agreement was fully recognized in 2013.

(2)
We revised the estimated performance period for the MABA program based on its progress as follows: (i) in the fourth quarter of 2011, resulting in an increase to net loss of $0.2 million for the year ended December 31, 2011, (ii) in the fourth quarter of 2012, resulting in an increase to net loss of $0.1 million for the year ended December 31, 2012 and (iii) in the fourth quarter of 2013, resulting in an increase to net loss of $0.1 million for the year ended December 31, 2013. We do not expect that these revisions will have a material impact on future revenue recognized under this program.
Schedule of revenue recognized under the Astellas collaboration agreement

 

 

 
   Year Ended December 31,  
(In thousands)
  2013   2012   2011  

Recognition of deferred revenue

   $ —   $ 125,819   $ —  

Amortization of deferred revenue

     —     —     12,975  

Royalties from net sales of VIBATIV®

     —     —     2,422  

Proceeds from VIBATIV® delivered to Astellas

     —     —     1,171  

Cost of VIBATIV® delivered to Astellas

     —     —     (1,177 )

Cost of unrealizable VIBATIV® inventories

     —     —     (537 )

Astellas-labeled product sales allowance

     —     (31 )   —  
               
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Total net revenue from Astellas

   $ —   $ 125,788   $ 14,854  
               
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
               
Summary of reductions to R&D expenses related to the reimbursement payments

 

 

 
   Year Ended December 31,  
(In thousands)
  2013   2012   2011  

GSK

   $ 473   $ 168   $ 449  

Merck

     4,937     756     —  

Alfa Wasserman

     1,500     185     —  

R-Pharm

     86     —     —  

Astellas

     —     —     390  
               
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Total reduction to R&D expense

   $ 6,996   $ 1,109   $ 839  
               
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​